This page shows the latest diroximel fumarate news and features for those working in and with pharma, biotech and healthcare.
Biogen’s Vumerity (diroximel fumarate) has been approved by the Scottish Medicines Consortium (SMC) as an oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). ... The SMC based its decision on results from pivotal phase 3
The Committee for Medicinal Products for Human Use (CHMP) has recommended Vumerity (diroximel fumarate) for patients with relapsing-remitting multiple sclerosis (RRMS) in the European Union. ... The active ingredient, monomethyl fumarate, reduces the
Orelabrutinib will fit neatly into Biogen’s MS portfolio, which includes Tecfidera (dimethyl fumarate), Tysabri (natalizumab) and Vumerity (diroximel fumarate).
In addition to the Tysabri data, Biogen also disclosed findings on the use of Vumerity (diroximel fumarate) in a real-world setting.
The challenge from Mylan focused on Biogen’s ‘514 patent on Tecfidera (dimethyl fumarate) , which is due to expire in 2028. ... Biogen does, however, have its own next-generation MS treatment – Vumerity (diroximel fumarate) – which was recently
Biogen and partner Alkermes scored FDA approval for Vumerity (diroximel fumarate) on the 30 October for the treatment of relapsing forms of MS. ... In comparison, Biogen’s older oral MS drug Tecfidera (dimethyl fumarate) entered the market with a price
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...